Clinical trials
Soft Tissue Lesion clinical trials
Below are recruiting soft tissue lesion clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT04757337RecruitingPhase 3
Oral chemotherapy comparison for older advanced soft-tissue cancer
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
ToulouseAges 65 years+ - NCT06837688Recruiting
Comparing two methods to improve gum around a single front tooth implant
This study compares two methods to improve gum tissue around a single dental implant in the front upper jaw. It may help you if you have a missing front tooth, healthy gums, and enough bone and gum width for an implant.
DamascusAges 18–60 - NCT07062003Recruiting
Minibeam radiation for skin or soft tissue tumors
This trial tests a new type of radiation called minibeam therapy for people with skin or soft tissue cancers that have come back or spread. It's designed to help shrink tumors that standard treatments haven't worked well for, and it uses a special device to focus the radiation more precisely.
Rochester, MinnesotaAges 18 years+ - NCT07470008Recruiting
Registry study for histotripsy in adults with soft tissue tumors
This study is a registry for adults getting histotripsy—a non-invasive ultrasound that breaks down soft tissue tumors—at UCSF. Joining means researchers can follow your treatment and outcomes to learn more about how well histotripsy works.
San Francisco, CaliforniaAges 18 years+ - NCT06537596RecruitingPhase 1
Imaging test for soft tissue sarcoma and other tumors
This study tests an imaging agent that may help see tumors with a specific protein called PDGFR alpha. It may help doctors better understand your cancer and plan treatment.
Brisbane, QueenslandAges 18 years+ - NCT05679921RecruitingPhase 2
Pazopanib, with or without pembrolizumab, for metastatic soft-tissue cancer
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
SeoulAges 20–80 - NCT06506838RecruitingPhase 4
Anlotinib, chemo, and radiation before sarcoma surgery
This trial tests combining anlotinib (a targeted therapy), doxorubicin (chemotherapy), and radiation given before surgery to shrink high-grade soft tissue sarcomas. The goal is to make the tumor easier to remove and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT06980259Recruiting
Comparing two types of radiation for soft tissue sarcoma
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
Jinan, ShandongAges 18–70 - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT07243626RecruitingPhase 2
Envafolimab plus chemo for advanced soft tissue sarcoma
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
Hanzhong, ZhejiangAges 18 years+ - NCT07602049RecruitingPhase 2
Freezing Plus Immunotherapy for Advanced Soft Tissue Sarcoma
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
Guangzhou, GuangdongAges 14–70 - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT05894018RecruitingPhase 2
Seed radiation plus fluzoparib for advanced soft tissue sarcoma
This trial tests whether combining seed radiation (iodine-125 placed in/near the tumor) with fluzoparib can better control advanced, hard-to-remove soft tissue sarcoma. It may help shrink tumors and slow progression, but you must meet several cancer, health, and safety requirements.
Guangzhou, GuangdongAges 18 years+ - NCT05961761RecruitingPhase 2
Testing propranolol plus pembrolizumab for advanced sarcoma
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
AarhusAges 18 years+ - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07052383RecruitingPhase 1
DIT309 for advanced bone and soft tissue sarcomas
This trial tests a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcoma that hasn't responded to standard treatments. It aims to see if this therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 8 years+ - NCT06367075RecruitingPhase 2
Cadonilimab plus adriamycin for advanced soft tissue sarcoma
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
Wuhan, HubeiAges 18–75 - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT05468970Recruiting
Study of bone and soft tissue tumors and treatment outcomes
This study looks at people with bone or soft tissue tumors to understand their features, treatments used, and survival outcomes. It may help doctors learn which care approaches work best for different tumor subtypes.
Zhengzhou, HenanAges 6–99 - NCT06171282RecruitingEarly Phase 1
Virus therapy for advanced bone and soft tissue tumors
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
ShanghaiAges 16–75 - NCT06760221Recruiting
Spotlight on bone cancer: SBRT plus surgery
This trial tests if giving a high dose of focused radiation (SBRT) before surgery can improve outcomes for people with aggressive soft tissue sarcoma in an arm or leg. You may be able to avoid chemotherapy and still have a good result.
Hangzhou, ZhejiangAges 18–80
Hear when a new Soft Tissue Lesion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Soft Tissue Lesion trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for soft tissue lesion?
- Yes. Clin2 currently lists 90 recruiting soft tissue lesion studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a soft tissue lesion trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a soft tissue lesion trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.